All change at biopharmas this week, as we reveal the industry movers at four biologics firms. Plus, which company is making board hires after a $52m private placement?
Oncology biotech Seattle Genetics has shaken up its executive team with five appointments.
Chris Boerner has been promoted to Executive VP, Commercial and Charles Romp has been made Senior VP, Sales.
Within the legal team, Kirk Schumacher moves up to Senior VP, Legal Affairs and Compliance, as well as General Counsel. Mark Sandbaken has been made VP, Intellectual Property.
David Fontana, an outside hire from the Early Clinical and Translational Research unit at Bristol-Myers Squibb, has been named VP, Portfolio and Program Management and program director for Adcetris (Brentuximab Vedotin), the company’s lead antibody-drug conjugate for treatment of Hodgkin Lymphoma.
“Chris and Chip have played key roles in the successful launch and ongoing commercialization of Adcetris in the US and Canada,” said Clay B. Siegall, President and CEO of Seattle Genetics. He added “Kirk and Mark have been key leaders of the legal group for many years, successfully managing our legal, compliance and intellectual property functions.”
Chris Boerner served as Senior VP, Commercial, before becoming Executive Vice President. He will oversee all sales and marketing for Adcetris.
Seattle Genetics holds commercialization rights for Adcetris in the US and Canada, while the Japanese company Takeda Pharmaceutical has all rights elsewhere.
Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
The world’s largest modular cGMP biopharmaceutical manufacturing facility came online this week in Wuhan, China.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...